Adrenomed AG

AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock

Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update

Adrenomed appoints Dr. Stephan Witte as Chief Medical Officer

Adrenomed appoints David Germonpré as Chief Financial Officer

Adrenomed appoints Dr. med. Steffen Stürzebecher as Chief Medical Officer

PEI Regulatory Approval Received for Government Funded Clinical Trial Investigating Adrenomed’s Adrecizumab in Treating Endothelial Barrier Dysfunction in Hospitalized COVID-19 Patients

Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO

Adrenomed Receives Positive EMA Scientific Advice for Further Clinical Development of Adrecizumab in Septic Shock

Adrenomed: Participation in Upcoming Scientific and Industry Events

Adrenomed Supervisory Board appoints Dr. Wolfgang Baiker as CEO

Efficacy Data from Adrenomed’s AdrenOSS-2 Phase II trial evaluating Adrecizumab (HAM8101) in Septic Shock presented at DIVI

Adrenomed closes EUR 22 million equity financing to accelerate development of Adrecizumab (HAM8101) and provides business update

Positive Results from Adrenomed’s AdrenOSS-2 Phase II trial evaluating Adrecizumab (HAM8101) in Septic Shock presented during e-ISICEM

Data from Adrenomed’s AdrenOSS-2 trial with Adrecizumab in Septic Shock to be presented during e-ISICEM

Targeting endothelial barrier function in critically ill COVID-19 patients: Adrecizumab shows beneficial effects

Adrenomed to Present New Topline Data from AdrenOSS-2 Phase II Trial in Virtual Meeting Hosted by Sepsis Comprehensive Center Charité

Adrenomed Announces Positive Top-Line AdrenOSS-2 Phase II Results with Adrecizumab in Septic Shock

Adrenomed completes full enrollment with 300 patients in AdrenOSS-2 trial with Adrecizumab in septic shock

Adrenomed Supervisory Board appoints Jens Schneider-Mergener as CEO and Jens Zimmermann, CMO, joins the Executive Board

Adrenomed’s Adrecizumab successfully passes interim analysis in early septic shock study AdrenOSS-II

Adrenomed AG announces publication of Phase II trial design of Adrecizumab to treat septic shock

International Opinion Leaders Align on Value of Adrenomedullin as Therapeutical Target and Biomarker in Sepsis and Acute Heart Failure

Adrenomed closes EUR 24 M financing led by Wellington and HBM